These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24591578)

  • 1. Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR.
    Xu Z; Pissarra LS; Farinha CM; Liu J; Cai Z; Thibodeau PH; Amaral MD; Sheppard DN
    J Physiol; 2014 May; 592(9):1931-47. PubMed ID: 24591578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
    Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
    Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects.
    Bompadre SG; Sohma Y; Li M; Hwang TC
    J Gen Physiol; 2007 Apr; 129(4):285-98. PubMed ID: 17353351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel.
    Cai Z; Taddei A; Sheppard DN
    J Biol Chem; 2006 Jan; 281(4):1970-7. PubMed ID: 16311240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
    Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.
    Liu J; Bihler H; Farinha CM; Awatade NT; Romão AM; Mercadante D; Cheng Y; Musisi I; Jantarajit W; Wang Y; Cai Z; Amaral MD; Mense M; Sheppard DN
    Br J Pharmacol; 2018 Apr; 175(7):1017-1038. PubMed ID: 29318594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G551D mutation impairs PKA-dependent activation of CFTR channel that can be restored by novel GOF mutations.
    Wang W; Fu L; Liu Z; Wen H; Rab A; Hong JS; Kirk KL; Rowe SM
    Am J Physiol Lung Cell Mol Physiol; 2020 Nov; 319(5):L770-L785. PubMed ID: 32877225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.
    Cai Z; Palmai-Pallag T; Khuituan P; Mutolo MJ; Boinot C; Liu B; Scott-Ward TS; Callebaut I; Harris A; Sheppard DN
    J Physiol; 2015 Jun; 593(11):2427-46. PubMed ID: 25763566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S; Li C; Ramjeesingh M; Bear CE
    Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR.
    Wang Y; Liu J; Loizidou A; Bugeja LA; Warner R; Hawley BR; Cai Z; Toye AM; Sheppard DN; Li H
    Br J Pharmacol; 2014 Oct; 171(19):4490-503. PubMed ID: 24902474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of F508del-CFTR by RXR motif inactivation triggers proteome modulation associated with the unfolded protein response.
    Gomes-Alves P; Couto F; Pesquita C; Coelho AV; Penque D
    Biochim Biophys Acta; 2010 Apr; 1804(4):856-65. PubMed ID: 20044041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanosensitivity of wild-type and G551D cystic fibrosis transmembrane conductance regulator (CFTR) controls regulatory volume decrease in simple epithelia.
    Xie C; Cao X; Chen X; Wang D; Zhang WK; Sun Y; Hu W; Zhou Z; Wang Y; Huang P
    FASEB J; 2016 Apr; 30(4):1579-89. PubMed ID: 26683699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A.
    Lopes-Pacheco M; Bacalhau M; Ramalho SS; Silva IAL; Ferreira FC; Carlile GW; Thomas DY; Farinha CM; Hanrahan JW; Amaral MD
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs.
    Miki H; Zhou Z; Li M; Hwang TC; Bompadre SG
    J Biol Chem; 2010 Jun; 285(26):19967-75. PubMed ID: 20406820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
    Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
    Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
    Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
    J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
    Yu YC; Sohma Y; Hwang TC
    J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
    Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
    Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the interactions between nucleotide binding domains and membrane spanning domains in cystic fibrosis transmembrane regulator: A molecular dynamic study.
    Belmonte L; Moran O
    Biochimie; 2015 Apr; 111():19-29. PubMed ID: 25640670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.